Binesh Balachandran1, Sourabh Dutta2, Ramandeep Singh3, Rajendra Prasad3, Praveen Kumar1. 1. Neonatal Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India. 2. Neonatal Unit, Department of Pediatrics, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India sourabhdutta1@gmail.com. 3. Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
Abstract
OBJECTIVE: To study the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants. STUDY DESIGN: Randomized, double-blind, placebo-controlled pilot trial. PARTICIPANTS: Neonates with birth weight ≤1500 g, gestation ≤32 weeks and postnatal age ≤96 h. INTERVENTION: Enteral bovine colostrum or placebo, four times a day, till 21 days of life or discharge or death. MAIN OUTCOME MEASURES: Definite NEC. Secondary outcomes included sepsis, mortality and stool interleukin-6 (IL-6) levels. RESULTS: Of the total 86 subjects (43 in each group), there were no statistically significant in the main outcome measures. In the colostrum group, there were trends toward higher stool IL-6 values and higher incidence of ileus and radiological signs of NEC. CONCLUSION: The use of prophylactic enteral bovine colostrum in VLBW infants shows a trend toward increased stool IL-6 and features of NEC. We were unable to detect clinical benefits.
RCT Entities:
OBJECTIVE: To study the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants. STUDY DESIGN: Randomized, double-blind, placebo-controlled pilot trial. PARTICIPANTS: Neonates with birth weight ≤1500 g, gestation ≤32 weeks and postnatal age ≤96 h. INTERVENTION: Enteral bovine colostrum or placebo, four times a day, till 21 days of life or discharge or death. MAIN OUTCOME MEASURES: Definite NEC. Secondary outcomes included sepsis, mortality and stool interleukin-6 (IL-6) levels. RESULTS: Of the total 86 subjects (43 in each group), there were no statistically significant in the main outcome measures. In the colostrum group, there were trends toward higher stool IL-6 values and higher incidence of ileus and radiological signs of NEC. CONCLUSION: The use of prophylactic enteral bovine colostrum in VLBW infants shows a trend toward increased stool IL-6 and features of NEC. We were unable to detect clinical benefits.
Authors: Rían Hayes; Jack Hartnett; Gergana Semova; Cian Murray; Katherine Murphy; Leah Carroll; Helena Plapp; Louise Hession; Jonathan O'Toole; Danielle McCollum; Edna Roche; Elinor Jenkins; David Mockler; Tim Hurley; Matthew McGovern; John Allen; Judith Meehan; Frans B Plötz; Tobias Strunk; Willem P de Boode; Richard Polin; James L Wynn; Marina Degtyareva; Helmut Küster; Jan Janota; Eric Giannoni; Luregn J Schlapbach; Fleur M Keij; Irwin K M Reiss; Joseph Bliss; Joyce M Koenig; Mark A Turner; Christopher Gale; Eleanor J Molloy Journal: Pediatr Res Date: 2021-11-06 Impact factor: 3.756
Authors: Yanqi Li; Sandra M Juhl; Xuqiang Ye; René L Shen; Elisabeth Omolabake Iyore; Yiheng Dai; Per T Sangild; Gorm O Greisen Journal: Front Pediatr Date: 2017-03-03 Impact factor: 3.418
Authors: Elise Mank; Eva F G Naninck; Jacqueline Limpens; Letty van Toledo; Johannes B van Goudoever; Chris H P van den Akker Journal: Nutrients Date: 2020-09-24 Impact factor: 5.717
Authors: Monica Guberti; Stefano Botti; Maria Teresa Capuzzo; Sara Nardozi; Andrea Fusco; Andrea Cera; Laura Dugo; Michela Piredda; Maria Grazia De Marinis Journal: Nutrients Date: 2021-06-25 Impact factor: 5.717